ASMB
Assembly Biosciences, Inc. NASDAQ Listed Dec 17, 2010$30.80
Mkt Cap $489.5M
52w Low $11.64
68.3% of range
52w High $39.71
50d MA $28.58
200d MA $28.30
P/E (TTM)
-49.8x
EV/EBITDA
-27.1x
P/B
1.5x
Debt/Equity
0.0x
ROE
-3.0%
P/FCF
-9.3x
RSI (14)
—
ATR (14)
—
Beta
1.16
50d MA
$28.58
200d MA
$28.30
Avg Volume
96.4K
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
331 Oyster Point Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.51 | 2.48 | +586.3% | 27.51 | +9.5% | +3.5% | +0.4% | -1.2% | +1.6% | +0.7% | — |
| Nov 10, 2025 | AMC | -0.50 | -0.72 | -44.0% | 32.07 | +0.1% | +3.3% | +8.2% | -0.9% | +3.4% | -1.0% | — |
| Aug 6, 2025 | AMC | -0.65 | -1.33 | -103.6% | 19.43 | -1.5% | +9.2% | +13.0% | -1.5% | +1.7% | +3.2% | — |
| May 8, 2025 | AMC | -2.01 | -1.17 | +41.8% | 11.66 | +2.9% | +5.0% | +0.9% | -0.1% | -1.9% | +3.2% | — |
| Mar 20, 2025 | AMC | -1.75 | -1.57 | +10.3% | 10.69 | +2.9% | +3.0% | +1.0% | +2.7% | -5.3% | +0.8% | — |
| Nov 7, 2024 | AMC | -2.02 | -1.51 | +25.2% | 17.50 | -2.1% | -4.1% | -2.2% | +1.0% | +0.8% | +2.1% | — |
| Aug 8, 2024 | AMC | -2.96 | -1.98 | +33.1% | 13.38 | -6.7% | -2.8% | +0.5% | +14.1% | -6.0% | +0.3% | — |
| May 8, 2024 | AMC | -2.74 | -1.66 | +39.4% | 12.85 | +2.7% | +1.2% | +3.0% | -0.1% | +3.8% | +5.1% | — |
| Mar 27, 2024 | AMC | -2.88 | -2.15 | +25.3% | 13.38 | -1.3% | -0.6% | -3.0% | +4.7% | +2.1% | -1.1% | — |
| Nov 8, 2023 | AMC | -2.76 | -3.24 | -17.4% | 10.20 | +1.2% | -11.8% | +0.0% | -6.7% | -1.4% | +7.2% | — |
| Aug 9, 2023 | AMC | -3.48 | -3.84 | -10.3% | 12.72 | -1.9% | +0.9% | -1.9% | -4.8% | -1.0% | -4.0% | — |
| May 4, 2023 | AMC | -4.44 | -4.44 | +0.0% | 12.48 | -3.8% | -1.0% | +1.0% | +2.9% | +2.8% | -3.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6 | Guggenheim | Maintains | Buy → Buy | — | $29.01 | $29.94 | +3.2% | +0.7% | -2.4% | +2.9% | +1.7% | -4.8% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.67 | $28.65 | -0.1% | +0.7% | -4.1% | -3.8% | +4.2% | +6.1% |
| Dec 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.26 | $35.65 | +1.1% | +2.6% | -9.5% | +3.9% | -1.1% | -0.9% |
| Nov 20 | Mizuho | Maintains | Outperform → Outperform | — | $38.00 | $38.77 | +2.0% | -3.3% | +4.8% | -1.5% | -1.3% | -0.6% |
| Oct 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.66 | $27.67 | +0.0% | +2.6% | +0.2% | +2.3% | +1.3% | +4.6% |
| Sep 8 | Guggenheim | Maintains | Buy → Buy | — | $23.82 | $25.05 | +5.2% | -2.1% | -0.7% | -3.8% | +1.5% | -3.3% |
| Mar 24 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $11.01 | $11.01 | +0.0% | +1.0% | +2.7% | -5.3% | +0.8% | -2.6% |
| Dec 27 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $15.38 | $15.38 | +0.0% | -1.4% | +5.7% | -1.6% | +8.7% | +2.0% |
| Mar 23 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $14.04 | $14.40 | +2.6% | -8.5% | -2.8% | -5.8% | -6.1% | -3.3% |
| Nov 15 | Mizuho | Maintains | Buy → Buy | — | $17.40 | $17.52 | +0.7% | -4.1% | -5.0% | +4.5% | -2.2% | +4.4% |
| Oct 23 | Truist | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Mar 31 | Truist | Maintains | Buy → Buy | — | $24.96 | $25.20 | +1.0% | -1.0% | +0.0% | +2.9% | -1.4% | +5.3% |
| Sep 13 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $38.76 | $38.64 | -0.3% | +2.2% | -1.2% | -1.8% | +0.6% | +0.3% |
| Sep 1 | William Blair | Downgrade | Outperform → Market Perform | — | $45.60 | $45.72 | +0.3% | +2.6% | -16.2% | -0.3% | -1.8% | -1.2% |
| May 9 | SVB Leerink | Maintains | Market Perform → Market Perform | — | — | — | — | — | — | — | — | — |
| Mar 22 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $58.20 | $58.20 | +0.0% | -3.3% | -5.1% | -2.7% | +3.0% | +0.2% |
| Nov 5 | Jefferies | Downgrade | Buy → Hold | — | $192.48 | $195.12 | +1.4% | -0.9% | -69.4% | +14.4% | -1.6% | -2.4% |
| Oct 19 | Truist | Maintains | Buy → Buy | — | $187.44 | $198.00 | +5.6% | -0.4% | -1.3% | +0.8% | -0.4% | -3.6% |
| Jul 7 | SVB Leerink | Maintains | Outperform → Outperform | — | $276.84 | $274.92 | -0.7% | +3.6% | +1.3% | -2.6% | -2.4% | -0.1% |
| Oct 16 | Mizuho | Maintains | Buy → Buy | — | $111.60 | $126.84 | +13.7% | +36.8% | +21.9% | -3.0% | +0.1% | -6.6% |
| Oct 8 | B. Riley FBR | Upgrade | Neutral → Buy | — | $319.80 | $357.48 | +11.8% | -2.3% | -2.8% | -2.2% | -4.7% | +1.8% |
| Oct 7 | B. Riley Securities | Upgrade | Neutral → Buy | — | — | — | — | — | — | — | — | — |
| Aug 8 | Baird | Maintains | Outperform → Outperform | — | $502.44 | $534.48 | +6.4% | +1.8% | -7.1% | -0.1% | -0.0% | -5.6% |
| May 8 | B. Riley FBR | Maintains | Neutral → Neutral | — | $531.36 | $525.24 | -1.2% | -7.3% | +2.3% | -4.7% | +1.5% | +3.7% |
| May 7 | B. Riley Securities | Maintains | Neutral → Neutral | — | $539.04 | $538.56 | -0.1% | -1.4% | -7.3% | +2.3% | -4.7% | +1.5% |
| Apr 12 | Chardan Capital | Downgrade | Buy → Neutral | — | $603.48 | $603.60 | +0.0% | -3.4% | -7.7% | +0.2% | +5.9% | -2.0% |
| Jan 5 | B. Riley FBR | Maintains | Neutral → Neutral | — | $538.92 | $538.80 | -0.0% | -4.0% | -3.3% | +0.1% | +5.4% | +1.5% |
| Nov 8 | Jefferies | Maintains | Buy → Buy | — | $389.04 | $394.56 | +1.4% | +8.4% | +0.0% | -3.8% | -1.4% | -0.8% |
No insider trades available.
8-K · 2.02
!! High
Assembly Biosciences, Inc. -- 8-K 2.02: Earnings Results
Assembly Biosciences reported quarterly earnings results; investors should review the attached press release for specific financial performance metrics and guidance updates affecting the ASMB and GILD stock valuations.
May 7
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
ASMB's new executive compensation structure ties pay to specific departmental and company-wide performance metrics, signaling management expects accountability for results and may improve operational efficiency.
Mar 30
8-K
Unknown — 8-K Filing
Assembly Biosciences' optimistic 2025 guidance and pivot toward viral disease therapeutics could drive share appreciation if pipeline candidates advance, but investors should verify clinical progress claims against actual trial data.
Mar 19
Data updated apr 24, 2026 7:15pm
· Source: massive.com